A21

A21 Therapeutics is a biotechnology company focused on the discovery and development of next-generation antiviral therapies for respiratory viruses. Founded by a team of industry veterans from Gilead Sciences and AbbVie, the company leverages deep expertise in virology and medicinal chemistry to create potent, broad-spectrum small molecule inhibitors. Their primary focus includes high-burden diseases such as respiratory syncytial virus (RSV), influenza, and coronaviruses. A21's approach targets highly conserved viral mechanisms to ensure efficacy against emerging variants and to minimize the risk of drug resistance. The company is backed by top-tier life science investors and is headquartered in the San Francisco Bay Area.